12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-06), Baxalta's 12-1 Month Momentum % is N/A%.
The industry rank for Baxalta's 12-1 Month Momentum % or its related term are showing as below:
BXLT's 12-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -21.06 * Ranked among companies with meaningful 12-1 Month Momentum % only.
Competitive Comparison of Baxalta's 12-1 Month Momentum %
For the Biotechnology subindustry, Baxalta's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Baxalta's 12-1 Month Momentum % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Baxalta's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Baxalta's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Baxalta 12-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of Baxalta's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Baxalta Inc was incorporated on September 8, 2016. It is a biopharmaceutical company engaged in the field of unmet medical needs covering various diseases which includes haemophilia, immunology and oncology. The Company develops, manufactures and markets a diverse portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions, as well as oncology treatments for acute lymphoblastic leukemia. It also invests in emerging technology platforms, including gene therapy and biosimilars. Its competitors include Advate, Feiba, Gammagard. The Company is subject to rules and regulations put forth by the jurisdiction it operates in.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BXLT has been successfully added to your